Join us for an engaging peer discussion on in-house 3D post-processing. Discover how top programs nationwide are evolving their labs and leveraging advanced visualization software, AI, and automation to enhance efficiency for both physicians and technologists.
Listen in as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis.
Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
Diagnosing female patients with coronary artery disease (CAD) has many challenges. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating these difficulties, and the guidelines and pathways that help with diagnosis and management of women with suspected CAD.
Join us for an engaging peer discussion on in-house 3D post-processing. Discover how top programs nationwide are evolving their labs and leveraging advanced visualization software, AI, and automation to enhance efficiency for both physicians and technologists.
Listen in as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis.
Duke University Health System has integrated Barostim into its comprehensive heart failure program. For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Listen in as an advanced heart failure specialist discusses patient selection and post-implant management, the implant procedure, patient care pathways, and how Duke has incorporated Barostim into their system.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
Diagnosing female patients with coronary artery disease (CAD) has many challenges. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating these difficulties, and the guidelines and pathways that help with diagnosis and management of women with suspected CAD.
Most advancements in electrophysiology technology are small and incremental, but the experts at Texas Cardiac Arrhythmia Institute in Austin, TX, were quick to see distinct advantages when they started using the latest iteration of radio frequency ablation, the QDOT MICRO™ Catheter.
Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.
If you’re looking to grow your CCTA program or start one, listen in. Learn from cardiology and radiology experts at Wellstar Health System who have built a successful CCTA program.
